Effects of Benfotiamine and AGE on Endothelial Function in People With Diabetes (AGE-Benfo)
Primary Purpose
Endothelial Dysfunction, Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 4
Locations
Germany
Study Type
Interventional
Intervention
Benfotiamine 1050mg, 3 days
high-AGE vs. low-AGE meal
Sponsored by

About this trial
This is an interventional prevention trial for Endothelial Dysfunction focused on measuring endothelial dysfunction, flow-mediated dilatation, advanced glycation end products, postprandial
Eligibility Criteria
Inclusion Criteria:
- type 2 diabetes mellitus
- age: 35-70 years
Exclusion Criteria:
- Heart failure corresponding to NYHA- class III and IV
- history of stroke
- history of myocardial infarction
- unstable angina pectoris
- peripheral artery disease stadium IIb and more
- kidney disease (Creatinine > 1,8 mg/dl and/or creatinine clearance <50 ml/min calculated according to the Cockroft formula and/or macroalbuminuria >200 mg/l)
- malignant diseases
- chronical alcohol consumption (more than 50 ml of highly concentrated alcohol or equivalents / day)
- pregnancy or lactation
- potentially child- bearing women without sufficient contraception (sufficient contraception is defined as the use of a contraceptive method that has an efficiency of over 99% (according to CHMP/EWP/225/02)). A pregnancy test will be performed before the commencement of the study.
- arterial hypotonia (blood pressure<90/50 mmHg) or arterial hypertonia with systolic blood pressure >159 mmHg and/or diastolic blood pressure >99 mmHg
- arterial hypertonia requiring more than three antihypertensive agents
- advanced diabetes complications (subjects must have been investigated with regard to these complications maximum 6 months previously by a specialized physician) such as:
- proliferative diabetic retinopathy
- diabetic neuropathy requiring morphium derivatives
- patients with an acute foot syndrome
- HbA1c >10 %
- participation to other studies within the previous 3 months
Sites / Locations
- Heart and Diabetes Center NRW
Outcomes
Primary Outcome Measures
A high-AGE meal causes a more pronounced postprandial endothelial dysfunction comparing to a low-AGE meal in people with type 2 diabetes mellitus.
Secondary Outcome Measures
The influence of high-AGE vs. low-AGE meal on the laboratory parameters that mirror AGE-metabolism, oxidative stress, endothelial dysfunction and inflammation shall be investigated.
To investigate whether treatment with Benfotiamine 1050mg/day for 3 days has a protective effect on endothelial function after a high-AGE meal
Full Information
NCT ID
NCT00437008
First Posted
February 15, 2007
Last Updated
February 15, 2007
Sponsor
Ruhr University of Bochum
1. Study Identification
Unique Protocol Identification Number
NCT00437008
Brief Title
Effects of Benfotiamine and AGE on Endothelial Function in People With Diabetes
Acronym
AGE-Benfo
Official Title
Acute Effects of a Low-AGE vs. High-AGE Meal on Postprandial Endothelial Function in People With Type 2 Diabetes Mellitus. Protective Effects of Benfotiamine
Study Type
Interventional
2. Study Status
Record Verification Date
February 2007
Overall Recruitment Status
Completed
Study Start Date
November 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
January 2006 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Ruhr University of Bochum
4. Oversight
5. Study Description
Brief Summary
The purpose of the study is to determine whether there are differences in postprandial endothelial function following a high-AGE(Advanced Glycation End-products) meal vs. a low-AGE meal. We also intend to investigate if the therapy with 1050mg Benfotiamine for 3 days protects against the postulated deterioration of endothelial function after a high-AGE meal in people with type 2 diabetes mellitus.
Detailed Description
AGEs are a heterogeneous group of compounds formed by the nonenzymatic reaction of reducing sugars with proteins, lipids and nucleic acids. Diet has been recognized as an important exogenous source of AGEs. There is evidence for the implication of AGEs in the pathogenesis of diabetes-related complications, atherosclerosis, ageing processes or Alzheimer´s disease. Although, only little information exists about their effects in humans. The hypotheses of this study are that a high-AGE meal leads to a more important acute vascular dysfunction comparing to a low-AGE meal, and that a 1050mg/day Benfotiamine therapy for 3 days has a protective effect on the endothelial function.
Twenty-one people with type 2 diabetes shall be investigated in a randomized, single-blinded (investigator), cross-over design (please compare design description).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endothelial Dysfunction, Type 2 Diabetes Mellitus
Keywords
endothelial dysfunction, flow-mediated dilatation, advanced glycation end products, postprandial
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
Single
Allocation
Randomized
Enrollment
21 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Benfotiamine 1050mg, 3 days
Intervention Type
Behavioral
Intervention Name(s)
high-AGE vs. low-AGE meal
Primary Outcome Measure Information:
Title
A high-AGE meal causes a more pronounced postprandial endothelial dysfunction comparing to a low-AGE meal in people with type 2 diabetes mellitus.
Secondary Outcome Measure Information:
Title
The influence of high-AGE vs. low-AGE meal on the laboratory parameters that mirror AGE-metabolism, oxidative stress, endothelial dysfunction and inflammation shall be investigated.
Title
To investigate whether treatment with Benfotiamine 1050mg/day for 3 days has a protective effect on endothelial function after a high-AGE meal
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
type 2 diabetes mellitus
age: 35-70 years
Exclusion Criteria:
Heart failure corresponding to NYHA- class III and IV
history of stroke
history of myocardial infarction
unstable angina pectoris
peripheral artery disease stadium IIb and more
kidney disease (Creatinine > 1,8 mg/dl and/or creatinine clearance <50 ml/min calculated according to the Cockroft formula and/or macroalbuminuria >200 mg/l)
malignant diseases
chronical alcohol consumption (more than 50 ml of highly concentrated alcohol or equivalents / day)
pregnancy or lactation
potentially child- bearing women without sufficient contraception (sufficient contraception is defined as the use of a contraceptive method that has an efficiency of over 99% (according to CHMP/EWP/225/02)). A pregnancy test will be performed before the commencement of the study.
arterial hypotonia (blood pressure<90/50 mmHg) or arterial hypertonia with systolic blood pressure >159 mmHg and/or diastolic blood pressure >99 mmHg
arterial hypertonia requiring more than three antihypertensive agents
advanced diabetes complications (subjects must have been investigated with regard to these complications maximum 6 months previously by a specialized physician) such as:
proliferative diabetic retinopathy
diabetic neuropathy requiring morphium derivatives
patients with an acute foot syndrome
HbA1c >10 %
participation to other studies within the previous 3 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alin O Stirban, Dr
Organizational Affiliation
Heart and Diabetes Center NRW
Official's Role
Principal Investigator
Facility Information:
Facility Name
Heart and Diabetes Center NRW
City
Bad Oeynhausen
ZIP/Postal Code
32545
Country
Germany
12. IPD Sharing Statement
Learn more about this trial
Effects of Benfotiamine and AGE on Endothelial Function in People With Diabetes
We'll reach out to this number within 24 hrs